Natixis Advisors LLC boosted its holdings in Haleon PLC Sponsored ADR (NYSE:HLN – Free Report) by 429.8% in the fourth quarter, Holdings Channel reports. The institutional investor owned 10,003,941 shares of the company’s stock after acquiring an additional 8,115,633 shares during the quarter. Natixis Advisors LLC’s holdings in Haleon were worth $101,140,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds have also bought and sold shares of the company. First Eagle Investment Management LLC grew its stake in Haleon by 9.8% in the 3rd quarter. First Eagle Investment Management LLC now owns 3,056,951 shares of the company’s stock valued at $27,421,000 after buying an additional 273,044 shares in the last quarter. Cidel Asset Management Inc. purchased a new position in Haleon in the 3rd quarter valued at approximately $4,043,000. Optiver Holding B.V. purchased a new position in Haleon in the 3rd quarter valued at approximately $45,593,000. JPMorgan Chase & Co. grew its stake in Haleon by 36.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 11,984,672 shares of the company’s stock valued at $107,503,000 after buying an additional 3,207,986 shares in the last quarter. Finally, Third View Private Wealth LLC purchased a new position in Haleon in the 4th quarter valued at approximately $3,461,000. 6.67% of the stock is currently owned by hedge funds and other institutional investors.
Haleon Stock Down 1.5%
Shares of NYSE:HLN opened at $8.71 on Wednesday. The firm has a fifty day moving average price of $9.51 and a two-hundred day moving average price of $9.95. The company has a debt-to-equity ratio of 0.47, a current ratio of 0.92 and a quick ratio of 0.71. Haleon PLC Sponsored ADR has a one year low of $8.69 and a one year high of $11.30. The company has a market cap of $38.56 billion, a price-to-earnings ratio of 22.32, a PEG ratio of 2.01 and a beta of 0.13.
Analyst Upgrades and Downgrades
A number of research analysts recently weighed in on the stock. Deutsche Bank Aktiengesellschaft reiterated a “sell” rating on shares of Haleon in a research note on Thursday, April 30th. Wall Street Zen upgraded shares of Haleon from a “hold” rating to a “buy” rating in a research note on Saturday, March 21st. Finally, Argus upgraded shares of Haleon to a “strong-buy” rating in a research note on Tuesday, March 17th. Two research analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Haleon presently has an average rating of “Moderate Buy”.
Get Our Latest Analysis on Haleon
Haleon Company Profile
Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.
The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.
Recommended Stories
- Five stocks we like better than Haleon
- Marvell Stock Soars on NVIDIA’s Trillion-Dollar Nod
- FirstCash Turns Pawn Into a Growth Machine
- HubSpot Just Crushed the Bear Case—Is a Bigger Rally Ahead?
- Aggressive Insider Buying Signals Opportunity in 3 Risky Stocks
Want to see what other hedge funds are holding HLN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haleon PLC Sponsored ADR (NYSE:HLN – Free Report).
Receive News & Ratings for Haleon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haleon and related companies with MarketBeat.com's FREE daily email newsletter.
